• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Sequeira Ramona was granted 3,528 shares, increasing direct ownership by 43% to 11,686 units (SEC Form 4)

    5/9/25 7:58:49 PM ET
    $EW
    Industrial Specialties
    Health Care
    Get the next $EW alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sequeira Ramona

    (Last) (First) (Middle)
    ONE EDWARDS WAY

    (Street)
    IRVINE CA 92614

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Edwards Lifesciences Corp [ EW ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/09/2025 A 3,528(1) A $0.0000 11,686 D
    Common Stock 5,918 I By Trust
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These restricted stock units were granted on May 9, 2025 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
    Remarks:
    This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
    Linda J. Park, Attorney-in-Fact 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EW

    DatePrice TargetRatingAnalyst
    4/24/2025$80.00Neutral → Overweight
    Piper Sandler
    1/30/2025$75.00 → $90.00Hold → Buy
    Stifel
    1/16/2025$60.00Peer Perform → Underperform
    Wolfe Research
    12/16/2024Neutral → Buy
    BofA Securities
    10/11/2024$70.00Equal-Weight
    Morgan Stanley
    9/18/2024$85.00 → $70.00Buy → Hold
    Jefferies
    7/31/2024Neutral → Outperform
    Daiwa Securities
    7/29/2024Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $EW
    Financials

    Live finance-specific insights

    See more
    • Edwards Lifesciences Reports First Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

      4/23/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025

      Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and

      4/16/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Reports Fourth Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.581; adjusted2 EPS of $0.59, driven by strong top-line performance Presented results of two practice-changing FDA clinical trials, EARLY TAVR and TRISCEND II Reiterating 2025 constant currency sales growth of 8% - 10%; adjusted EPS of $2.40 - $2.50 Continuing to expect mid-year asymp

      2/11/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    SEC Filings

    See more
    • Edwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Edwards Lifesciences Corp (0001099800) (Filer)

      5/8/25 5:11:37 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Edwards Lifesciences Corporation

      10-Q - Edwards Lifesciences Corp (0001099800) (Filer)

      5/6/25 4:13:32 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form 144 filed by Edwards Lifesciences Corporation

      144 - Edwards Lifesciences Corp (0001099800) (Subject)

      5/5/25 4:03:54 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zovighian Bernard J covered exercise/tax liability with 4,245 shares, converted options into 6,265 shares and bought $49,753 worth of shares (580 units at $85.74), increasing direct ownership by 5% to 46,836 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/7/24 5:53:27 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Director Valeriani Nicholas J was granted 5,564 shares, increasing direct ownership by 8% to 79,296 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/9/25 7:58:51 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Director Sequeira Ramona was granted 3,528 shares, increasing direct ownership by 43% to 11,686 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/9/25 7:58:49 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Director Loranger Steven R was granted 4,682 shares, increasing direct ownership by 8% to 65,054 units (SEC Form 4)

      4 - Edwards Lifesciences Corp (0001099800) (Issuer)

      5/9/25 7:58:46 PM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Edwards Lifesciences from Neutral to Overweight and set a new price target of $80.00

      4/24/25 7:18:16 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences upgraded by Stifel with a new price target

      Stifel upgraded Edwards Lifesciences from Hold to Buy and set a new price target of $90.00 from $75.00 previously

      1/30/25 7:10:09 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences downgraded by Wolfe Research with a new price target

      Wolfe Research downgraded Edwards Lifesciences from Peer Perform to Underperform and set a new price target of $60.00

      1/16/25 7:43:13 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Leadership Updates

    Live Leadership Updates

    See more
    • Scaling its Investment Platform in Minimally Invasive Care, Intuitive Ventures Appoints Terri Burke as Senior Partner and Ross Jaffe as Venture Advisor

      Intuitive Ventures today announced the appointment of Terri Burke, former head medtech investments at Epidarex Capital and a seasoned operator, as Senior Partner and Dr. Ross Jaffe, a co-founder of Versant Ventures, as Venture Advisor. Both medtech veterans, they will help support the continued growth of Intuitive Ventures in investing in start-ups reimagining the future of minimally invasive care. With more than two decades of medtech investing and operational leadership experience, Burke will help support the growth of the firm's investment platform. With over $250 million in assets under management, Intuitive Ventures invests in founders tackling large, meaningful problems that positive

      3/6/25 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN

      IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre

      12/8/22 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Announces Updates From Annual Meeting

      IRVINE, Calif., May 5, 2021 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals: All eight director nominees were elected as directors of the company for a one-year term; Stockholders advised that they approve the compensation of the company's named executive officers; Stockholders have approved the Amendment and Restatement of the company's U.S. and International Employee Stock Purchase Plans; Stockholders have ratified the appoi

      5/5/21 9:15:00 AM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Edwards Lifesciences Corporation

      SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)

      11/8/24 10:34:33 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Edwards Lifesciences Corporation

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      10/4/24 2:14:28 PM ET
      $EW
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Edwards Lifesciences Corporation (Amendment)

      SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)

      2/13/24 5:04:42 PM ET
      $EW
      Industrial Specialties
      Health Care

    $EW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference

      Edwards Lifesciences (NYSE:EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and p

      5/6/25 7:05:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

      Transforming Care for Severe AS Patients Edwards Lifesciences (NYSE:EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance (watchful waiting). Wit

      5/1/25 8:00:00 AM ET
      $EW
      Industrial Specialties
      Health Care
    • Edwards Lifesciences Reports First Quarter Results

      Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth Q1 EPS of $0.622; adjusted1 EPS of $0.64 SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team Data from Hear

      4/23/25 4:15:00 PM ET
      $EW
      Industrial Specialties
      Health Care